Bioventix PLC, a biotechnology company, develops, manufactures, and supplies sheep monoclonal antibodies (SMAs) for use in immunodiagnostics focusing on the areas of clinical diagnostics and drugs of abuse testing. The company offers a portfolio of purified SMAs for a range of conditions, including thyroid, fertility, oncology, vitamin D, drugs of abuse, and other indications. It also offers contracting services for sheep monoclonal antibody creation. Bioventix PLC was incorporated in 2003 and is based in London, the United Kingdom.